Supreme Court lets pay-to-delay ruling against pharma stand

(By Ed Silverman for STAT)

Cash is not always king.

In a move that should settle a highly contentious legal issue, the US Supreme Court on Monday declined to hear an appeal1 of a ruling2 that said cash payments are not the only litmus test for determining whether a patent settlement between drug makers deserves antitrust scrutiny. Continue reading article here…


Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or